We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+6.61%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$1B
AUM Growth
+$47.9M
(+5%)
Cap. Flow
+$3.61M
Cap. Flow
% of AUM
0.36%
Top 10 Holdings %
Top 10 Hldgs %
53.49%
Holding
65
New
7
Increased
13
Reduced
12
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$12M |
| 2 |
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
|
+$10.2M |
| 3 |
Heron Therapeutics
HRTX
|
+$9.31M |
| 4 |
Viatris
VTRS
|
+$7.96M |
| 5 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$7.48M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$15.3M |
| 2 |
HOLX
Hologic
HOLX
|
+$9.94M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$8.51M |
| 4 |
Perrigo
PRGO
|
+$8.4M |
| 5 |
CELG
Celgene Corp
CELG
|
+$6.02M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.13% |
| 2 | Financials | 1.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLVS
51
DELISTED
Clovis Oncology, Inc.
CLVS
| $3.28M | 0.33% |
47,364
+14,706
| +45% | +$1.08M |
|
|
LITS
52
Lite Strategy Inc
LITS
$33.6M
| $2.71M | 0.27% |
12,196
| – | – |
|
|
NPSP
53
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $2.48M | 0.25% |
82,900
+20,100
| +32% | +$693K |
|
54
PTC Therapeutics
PTCT
$6.26B
| $2.07M | 0.21% |
+79,150
| New | +$2.13M |
|
|
BLUE
55
DELISTED
bluebird bio
BLUE
| $1.68M | 0.17% |
+5,709
| New | +$1.73M |
|
56
Achieve Life Sciences
ACHV
$647M
| $1.33M | 0.13% |
51
| – | – |
|
57
Supernus Pharmaceuticals
SUPN
$2.65B
| $1.26M | 0.13% |
140,800
| – | – |
|
|
AUXL
58
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| $1.15M | 0.11% |
42,165
-130,855
| -76% | -$3.47M |
|
|
SGMO
59
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $857K | 0.09% |
+47,400
| New | +$914K |
|
60
MacroGenics
MGNX
$240M
| $798K | 0.08% |
31,857
| – | – |
|
61
CVS Health
CVS
$134B
| – | – |
-53,694
| Closed | -$3.84M |
|
|
HOLX
62
DELISTED
Hologic
HOLX
| – | – |
-444,687
| Closed | -$9.94M |
|
63
Waters Corp
WAT
$37.3B
| – | – |
-9,700
| Closed | -$970K |
|
|
AVNR
64
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
| – | – |
-406,000
| Closed | -$1.36M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q1 2014 Portfolio in Review
As of Q1 2014, Tekla Capital Management held 65 positions worth $1B, up 5% from $952M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Tekla Capital Management's Q1 2014 filing shows 7 new, 13 increased, 12 reduced and 4 closed positions. Its largest new stake was Eiger BioPharmaceuticals, Inc.: 2,157 shares worth $9.83M. The largest sale was Regeneron Pharmaceuticals, an estimated $15.3M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 86% a quarter earlier, followed by Financials.
- Tekla Capital Management's largest Q1 2014 buy was Eiger BioPharmaceuticals, Inc.: 2,157 shares worth $9.83M.
- Tekla Capital Management added most to BioMarin Pharmaceuticals in Q1 2014, an estimated $12M increase.
- Tekla Capital Management's biggest Q1 2014 reduction was Regeneron Pharmaceuticals, cutting an estimated $15.3M.
- Tekla Capital Management fully exited Hologic in Q1 2014, selling an estimated $9.94M.
- Tekla Capital Management's ten largest holdings make up 53% of its $1B portfolio in Q1 2014.
- Tekla Capital Management opened 7 new positions and closed 4 in Q1 2014.
- Tekla Capital Management's portfolio value rose 5% quarter-over-quarter to $1B.
Based on Tekla Capital Management's 13F filing for Q1 2014, filed 13 May 2014.